Perspectives on cancer experiences with oncologist Dr. Willie Goffney

American Cancer Society

Share This Post

Feb 2023: Check out this tweet from the American Cancer Society that shares a conversation with Dr. Willie Goffney about her perspective on cancer. A tweet says, “Join Adam Lopez, host of Candid Conversations, as he discusses personal and professional perspectives on cancer experiences with oncologist Dr. Willie Goffney and community leader Tracie Kimbrough as part of the ongoing Diversity in Science campaign.” Check out this tweet from ACC below.

You can also watch the entire conversation on YouTube.


Check out the entire conversation on YouTube.

The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. We are the only organization working to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer. Learn more about who we are, what we do, and our plans for the future by exploring the areas below.

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (1). The most common in 2020 (in terms of new cases of cancer) were:

  • breast (2.26 million cases);
  • lung (2.21 million cases);
  • colon and rectum (1.93 million cases);
  • prostate (1.41 million cases);
  • skin (non-melanoma) (1.20 million cases); and
  • stomach (1.09 million cases).

The most common causes of cancer deaths in 2020 were:

  • lung (1.80 million deaths);
  • colon and rectum (916 000 deaths);
  • liver (830 000 deaths);
  • stomach (769 000 deaths); and
  • breast (685 000 deaths).

Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries. Cervical cancer is the most common in 23 countries. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy